TACE联合免疫药物与联合靶向药物治疗中晚期肝癌的疗效对比  

Comparison of efficacy of TACE combined with immunodrugs and combined targeted drugs in the treatment of advanced liver cancer

作　　者：罗帅 次旦旺久[1] 格桑罗布[1] 赵玉兰[1] 雷彦明[1] Luo Shuai;Ci Danwangjiu;Ge Sangluobu;Zhao Yulan;Lei Yanming(People's hospital of Tibet Autonomous Region,Lhasa 850000,China)

机构地区：[1]西藏自治区人民医院,西藏拉萨850000

出　　处：《西藏医药》2023年第6期15-17,共3页Tibetan Medicine

基　　金：西藏自治区人民医院院内课题(XZQYY2020018)。

摘　　要：目的 观察肝动脉化疗栓塞术(TACE)联合靶向治疗与肝动脉化疗栓塞术联合免疫治疗中晚期肝癌的临床疗效。方法 回顾性分析2018年1月~2022年4月在我院经临床及病理诊断为中晚期肝癌的患者88例。按治疗方案不同分为A组(36例),B组(52例)。A组采用TACE联合靶向治疗,B组采用TACE联合免疫治疗。比较两组治疗后第3个月、第6个月的客观缓解率(ORR)、疾病控制率(DCR)情况,并记录两组不良反应的发生情况。结果 B组ORR及DCR均高于A组,A组和B组3个月ORR率分别为22.22%、48.08%,DCR率分别为52.78%、80.77%,两组比较差异有统计学意义(P<0.05);A组和B组6个月ORR率分别为16.67%、43.14%,DCR率分别为46.67%、76.47%,差异有统计学意义(P<0.05);不良反应:两组差异无意义(p<0.05)。结论 TACE联合免疫治疗与TACE联合靶向治疗均安全,前者比后者在中晚期肝癌治疗中更加有效。Objective To observe the clinical efficacy of hepatic arterial chemoembolization(TACE)combined targeted therapy and TACE combined immunotherapy in the treatment of middle and advanced liver cancer.Methods The data of 88 patients with advanced liver cancer dignosed clinically and pathologically admitted to our hospital from January 2018 to April 2022 were retrospectively analyzed.They were divided into group A(36cases)and group B(52 cases)according to different treatment plans.TACE combined with targeted therapy was used as group A,and TACE combined with immunotherapy was used as group B.Objective response rate(ORR)and disease control rate(DCR)of the two groups were compared at 3rd and 6th months after treatment,and the occurrence of adverse reactions in the two groups were recorded.Results The ORR and DCR of group B were higher than those of group A.The 3-month ORR rates of group A and group B were 22.22%and 48.08%,and the DCR rates of group A and group B were 52.78%and 80.77%,respectively,And the differences was statistically significant(P<0.05).The 6-month ORR rates of group A and group B were 16.67%and 43.14%,and the DCR rates were 46.67%and 76.47%,respectively,with statistical significance(P<0.05).Adverse reactions:there was no significant difference between the two groups(P<0.05).Conclusion Both TACE combined immunotherapy and TACE combined targeted therapy are safe,and the former is more efective than the latter in the treatment of middle and advanced liver cancer.

关 键 词：中晚期肝癌 肝动脉化疗栓塞术 靶向治疗 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]